This trial is currently being conducted in the US by a clinical research organization, specializing in the conductance of Phase I studies. The drug is orally administered to healthy volunteers in sequential dose-escalating cohorts. The company plans to proceed to the next trial cohort with a higher dose. Can-Fite currently intends to develop CF102 for the treatment of liver cancer and other liver diseases.
Pnina Fishman, CEO of Can-Fite, said: “The initiation of a Phase I trial with CF102 and the success of its first cohort, promote Can-Fite to a status of a biotechnology company with two pipeline drugs in clinical trials.”